The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s male hypogonadism market report forecasts the male hypogonadism market size to grow to $4.48 Billion by 2027, with a CAGR (compound annual growth rate) of 6%.

Learn More On The Male Hypogonadism Market Report 2023 – https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

Male Hypogonadism Market Size Forecast
The global male hypogonadism market is expected to grow from $3.32 billion in 2022 to $3.55 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global male hypogonadism market size is expected to reach $4.48 billion in 2027 at a CAGR of 6.0%.

North America held the largest male hypogonadism market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Male Hypogonadism Market Driver ­– Increase In Infertility Rates
According to the Office for National Statistics, a UK-based statistics organisation, there were 613,936 live births in England and Wales in 2020, a significant 4.1% decrease from 2019. The total fertility rate (TFR) plummeted to an all-time low of 1.58 children per woman in 2020. As a result, the rate of infertility rose from 2019 to 2020. In addition, according to a 2021 study published in the Libyan Journal of Medical Sciences, male factors account for almost 70% of infertility in Libya. As a result, an increase in the rate of infertility is driving the expansion of the male hypogonadism market.

Request for A Sample Of The Global Male Hypogonadism Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9969&type=smp

Key Male Hypogonadism Market Trend – Product Innovations
Companies in the male hypogonadism market are developing new products to maintain their market position. For example, Halozyme, a biotechnology company based in the United States, will debut Tlando, an oral medication for testosterone replacement therapy in male hypogonadism, in June 2022. Tlando is a testosterone-containing prescription medicine that was approved by the FDA as the first oral testosterone treatment. It is used to treat adult men who have little or no testosterone as a result of various medical problems.

Male Hypogonadism Market Segment
1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types
2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries
3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy

Male Hypogonadism Market Major Players and Strategies
Major players in the male hypogonadism market are Allergan plc, Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech, Teva Pharmaceutical Industries Ltd., AbbVie Inc, Perrigo Company plc, AstraZeneca PLC, IBSA Institut Biochimique SA, Juniper Laboratories SA, and Sun Pharmaceutical Industries Limited.

Gruenenthal, a German pharmaceutical business, purchased Nebido from Bayer AG in July 2022 for €500 million ($551.32 million). The goal of this acquisition was to increase Gruenenthal’s profitability, allowing it to invest in R&D and produce the next generation of pain medicines. Bayer AG is a German pharmaceutical business that specialises in the treatment of male hypogonadism.

The Male Hypogonadism Global Market Report 2023 covers regional data on male hypogonadism market size, male hypogonadism market trends and drivers, opportunities, strategies, and male hypogonadism market competitor analysis. The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Male hypogonadism is a condition in which the body does not create enough testosterone. Testosterone is the principal male sex hormone and is required for male development and growth during puberty.

View More Reports Related To The Male Hypogonadism Market –
Maleic Anhydride Global Market Report 2023
Drugs For Hormonal Replacement Therapy Global Market Report 2023
Male Toiletries Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: